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Abstract
Chronic hepatitis B virus (HBV) infection affects 240 million people worldwide and
represents a significant burden on public health. Current antiviral treatment of chronic
hepatitis B mainly focuses on inhibiting viral replication. A main deficiency of the
current treatment is unable to protect uninfected liver cells or hepatocytes that cleared
HBV from next rounds of infection. HBV infection biology shows that natural clearance
of HBV cccDNA from infected cells frequently occurs, HBV infection including chronic
HBV infection is established and maintained by multiround infection, and the course
of HBV infection is largely determined by the number of round of infection. Thus, an
effective treatment of HBV infection must block new rounds of infection. A proposed
new strategy for treating chronic HBV infection aims to immediately interrupt infection
course and to achieve HbsAg seroconversion as early as possible. Under this strategy,
a main target of antiviral treatment is extracellular viruses, and an effective therapeutics
is specific neutralizing (anti-HBs) antibodies. A difference in tempo and efficiency of
treating HBV infection between current antivirals and neutralizing antibody is that the
antivirals inhibit viral infection only after cells are virus infected while the neutralizing
antibody clears viruses before the infection of cells takes place.
Keywords: hepatitis B virus, acute hepatitis B, chronic HBV infection, HBV infection
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1. Introduction: why we need a better understanding of HBV infection
biology?
Chronic hepatitis B virus (HBV) infection affects 240 million people worldwide [1]. Estimated
4.5 million of new HBV infection occurs each year [2]. A significant portion of new HBV infections
occurs in infants borne to HBV-positive mothers despite a fully scheduled HBV immunization.
More than 90% of HBV-infected infants will become chronic [3–5], resulting in constant expansion
of chronic HBV-infected population.
Chronic HBV infection can induce severe or repeated liver injury, which can lead to advanced
liver diseases including cirrhosis [6, 7] and hepatocellular carcinoma [8]. The disease burden
of HBV infection is enormous, and WHO reports that 780,000 people die of HBV-related liver
diseases or complications annually [9]. In addition, as many as 70% of chronic HBV-infected
patients who have persistently normal ALT already experienced significant alterations in liver
histology [10–13]. We need to provide more effective treatment to chronic HBV-infected
patients.
Current antiviral treatment is recommended for chronic HBV-infected patients who have
evidence of liver injury related to HBV infection [14, 15]. Antivirals that mainly consist of
nucleos/tide analogues can potently inhibit HBV replication, mitigate liver injury and slow-
down progression of necroinflammation in the liver [16, 17]. However, the current treatment
rarely clears chronic HBV infection. Majority of chronic HBV-infected patients are not suitable
for current antiviral treatment. Untreated patients, despite normal ALT history, can experience
unpredictable flare-ups of liver injury [18, 19]. Exacerbation insults, if occurred in patients with
chronic liver injury or significant alterations in liver histology despite normal ALT, can trigger
acute chronic liver failure with up to 70% mortality [20, 21].
Clearly, the current antiviral treatment strategy and available antivirals do not meet clinical
needs.
Here, we briefly discuss a number of limitations of current antiviral strategy and antivirals.
1.1. Current treatment strategy does not protect virus-cleared cells or uninfected cells from
new rounds of infection
Current antiviral therapy is guided by belief and strategy that a viral infection can be cleared
by directly inhibiting viral replication. This approach certainly mitigates viral diseases
associated with viral replication, even clears viral infection under certain circumstances, for
instance, a significant portion of chronic HCV infection can be cleared with a relatively short
course of direct-acting antiviral agents [22, 23]. However, it does not take consideration of viral
infection biology, which is featured with multiround infection (see below). This is why current
antiviral strategy cannot clear chronic HBV infection. The NA-based antiviral therapy for
chronic HBV infection, even with early generation of NAs like lamivudine, can clear HBV from
HBV-infected cells, evidence includes wild-type (WT) virus, or early viral population was
eliminated and replaced with drug-related mutant (MT) virus [24, 25]. Additional evidence
consists of 5–6 logs reduction of serum HBV DNA level [26, 27–29] and 100-fold reduction of
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intracellular total HBV DNA and cccDNA levels in treated animals and patients [30–32].
However, during the same period, serum HBsAg level is only reduced by two- to three fold
[33], suggesting HBsAg level remains constantly high. The enduring high level of HBsAg keeps
depleting the limited amount of endogenous neutralizing antibodies and leaves HBV virions
that are produced by infected cells in the same livers, unneutralized and infectious, which
continue to cause new rounds of infection. Under the current antiviral strategy, virus-cleared
cells can immediately become infected again, gains in clearing viral infection are continuously
reversed, and it is extremely difficult to establish permanent and complete viral clearance
under current antiviral strategy because virus-cleared cells and uninfected cells are not
protected.
1.2. Antivirals target viral replication in infected cells and do not directly act against
extracellular viruses
Two events occur simultaneously during antiviral therapy. One is viral replication is inhibited
intracellularly, and the other is new rounds of infection continue as long as there are unneu-
tralized extracellular viruses and susceptible cells that are not protected. Antivirals only
suppress viral replication in infected cells, reducing production of new viruses that will lower
level of extracellular viruses, which eventually lead to reducing new rounds of infection. Once
no more viruses available for new rounds of infection, the infection course is actually inter-
rupted, which brings the infection course to the end. Thus, the direct impact of treatment with
antivirals is to reduce viral replication while an indirect impact is leading to limiting spread
of infection, which really matters in containing and clearing viral infection. However, the
antivirals do not directly act against extracellular viruses that may continuously cause new
rounds of infection and compromise antiviral efficacy. This feature determines relatively
ineffectiveness of direct antivirals in treating chronic HBV infection.
1.3. Effectiveness of antivirals depends on HBV replication efficiency
The third issue is that antivirals do not inhibit or kill viruses that were already produced. They
only inhibit producing new viruses upon replication. Antivirals will not function if there was
no active viral replication. Actual effectiveness of an antiviral in treating hepatitis B is largely
determined by HBV replication efficiency. In clinic, a link between HBV replication level and
antiviral response has been indicated. For instance, in patients with long-term entecavir
therapy, a full virological response rate was 59, 84, 90, 93, and 95% after 48, 96, 144, 192, and
240 weeks of therapy, respectively [27]. Clearly, 59% of treated patients achieved the full
virological response to entecavir in the first 48 weeks, but only 16, 6, 3 and 2% of net increased
response were, respectively, achieved when the therapy was extended from 48 to 96, 144, 192
and 240 weeks. The net increased response rate was progressively declined along with
extending therapy period since the viral replication was increasingly depressed to very low
level. The replication-dependent effectiveness determines the direct antivirals are not effective
against HBV infection with inactive replication, for instance in anti-HBe–positive patients with
low HBV DNA level or only HBsAg positive patients.
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1.4. Ineffective against severe acute HBV diseases
Direct antivirals would not be effective in treating severe acute hepatitis B since they take a
few days or longer to significantly reduce viral replication or serum viral load (a log or greater)
[34–37]. They would take much longer time to mitigate pathologic injury and to improve
clinical manifestations [38]. Relatively slow action and no direct inhibition of extracellular
viruses highlight potential ineffectiveness of antivirals in treating fulminant hepatitis B and
acute severe exacerbation of chronic HBV infection-induced liver injury, both of which induce
rapidly deteriorated clinic course and high mortality [39–41].
1.5. Antivirals alone cannot completely clear viral infection
Antivirals may be no longer effective once the viral replication was inhibited to low level.
Residual viruses can be secreted out, or released by turnovers of infected cells, leading to
clearing infection or infected cells. The released residual viruses are small in quantity and can
be completely neutralized if there is relatively sufficient amount of endogenous neutralizing
antibodies, which lead to stopping the course of viral infection by blocking new rounds of
infection. This scenario likely happens to clearing chronic hepatitis C virus infection with direct
antivirals.
The released residual viruses following potent inhibition of virus production will still be
capable of causing new rounds of infection if there were no sufficient neutralizing antibodies,
prolonging the course of chronic infection. This scenario likely happens to antivirals-treated
HBV-infected patients.
Clearly, antivirals alone cannot complete clearing viral infection,which requires the presence
of sufficient neutralizing antibodies.
What we need is new treatment strategies and new therapeutics that can improve current
treatment approach and antivirals in treating chronic HBV infection.
We believe we can find effective solutions to current problems in treating chronic HBV infection
through a better understanding of HBV infection biology, which will also accelerate developing
new prophylactics and therapeutics.
2. Understanding HBV infection biology
2.1. Natural course of HBV infection
Infection biology is science illustrating fundamentals of infection, which is centered on
understanding how a productive infection is established and maintained. Understanding of
infection biology starts with understanding natural course of infection. In this review, we only
focus on the natural course of HBV infection that causes hepatitis. The natural course of
hepatitis B consists of initial infection, incubation period and clinical phase (Figure 1).
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Figure 1. Schematic illustration of a typical course of infection that consists of initial infection, incubation and clinical
phases. Progression of infection course is directly driven by new rounds of infections. It also suggests the infection
course can be ended at any stage as long as extracellular pathogens are completely neutralized.
2.1.1. Initial HBV infection
Initial infection represents beginning of an infection and it provides seed of infection and
usually consists of a few or small clusters of infected cells in the liver. The initial infection is
important, but it cannot become a full-blown infection without incubation period.
2.1.2. Incubation period
The incubation refers to a period between initial infection and appearance of clinical symp-
toms. Length of the incubation varies considerably from individual to individual, but it is
required for every HBV infection that causes hepatitis, which suggests the number of virus
involved in the initial infection is so small that cannot immediately cause significant injury or
clinical manifestations. Likely sequential events during the incubation include that infected
HBV replicates in initial infected cells, progeny viruses are released through secretion or/and
cytopathic destruction of infected cells, resulting in new rounds of infection of more cells, most
likely in neighboring areas because short distances between viruses and susceptible cells favor
higher efficiency of infection. Continuously released viruses keep initiating new rounds of
infections, infecting more cells and extending the scope of infection. When the number of
destructed cells reached an extent that causes clinical symptoms, the incubation is progressing
to clinical phase.
Requirement of incubation period in full-blown HBV infection provides evidence that more
than one round infection is required to establish and maintain a full-blown infection or
hepatitis B (Figure 1). Thus, acute hepatitis B is caused by multiround of infection.
A main factor that allows multiround of infection is that there is no sufficient amount of
endogenous neutralizing antibodies to neutralize the released viruses.
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New rounds of infections inevitably occur during the infection course as long as there are
unneutralized extracellular viruses and susceptible cells.
2.1.3. Clinical phase of acute HBV infection
Acute HBV infection in adults is a self-limiting disease, and 95% of them will be recovered
without treatment [42]. A unique kinetics of serum HBV DNA level during acute HBV infection
includes a rapid fall of HBV DNA level after the peak (Figure 2), suggesting HBV infection is
being progressively cleared from the liver, as evidenced by rising ALT level (a result of
destructing the infected cells) at the same time frame. Critically, it also suggests no new rounds
of HBV infection, implying a block of new rounds of infection is required for clearing HBV
infection. A mechanism behind these changes is called “HBsAg seroconversion,” a hallmark
for resolving HBV infection.
Figure 2. Kinetics of serum HBV DNA and ALT levels during acute hepatitis B. HBV DNA quickly falls after the peak,
which coincides with rising ALT level. The rapid fall of HBV DNA suggests no new round infection.
When destruction of the infected cells is started during acute HBV infection, it will initially
cause transit elevation of serum HBsAg and HBV DNA levels by releasing viral particles.
However, the serum HBsAg and HBV DNA levels will then keep falling because the number
of infected cells that supply and replenish serum HBsAg and HBV virion is progressively
reduced by the liver injury (the supply reduced) while the removal or the half-life of viral
particles from/in circulation should be at a constant rate, contributing to rapidly significant
reduction of serum HBsAg and HBV levels. At certain point, the relative ratio between amounts
of HBV particles (both viral and subviral particles) and anti-HBs antibodies will be reversed
from the former greatly exceeding the latter, to the latter exceeding the former (HBsAg
seroconversion). This conversion creates a sufficient anti-HBs capacity to clear serum HBsAg
and to block new round infection, which allows uninfected cells and cells that cleared HBV
infection permanently stay infection free. This process highlights an indispensable require-
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ment of anti-HBs antibodies in blocking new rounds of HBV infection and resolving HBV
infection.
Different impacts of liver injury on outcomes of infection are expected if occurred at different
frequencies. For instance, continuous or progressive liver injury at moderate or medium scale,
as is in acute hepatitis B, or at massive scale as is in fulminant hepatitis can lead to complete
clearance of HBV infection because of successful reversal of the ratio of serum HBsAg and anti-
HBs. On the other hand, if occurred intermittently, it unlikely leads to a complete viral clearance
as is in chronic hepatitis B because of no reversal of the ratio of HBsAg and anti-HBs. The
different outcomes once again emphasize that HBsAg seroconversion is critically required for
completely clearing HBV infection.
A HBV infection can be ended at any stage if subsequently released viruses were completely
neutralized by endogenous neutralizing antibodies. Most of HBV infections are aborted during
the incubation period without developing into a full-blown infection because relative amount
of infected viruses is still low. Those individuals who ended the HBV infection before clinical
stage only show detectable anti-HBs and anti-HBc antibodies without clinical manifestations
and noticeable HBV infection history [43, 44].
Thus, a natural strategy to clear viral infection or end infection course utilized by the host is
to include producing neutralizing antibodies to block new rounds of infection with newly
released viruses [45]. However, in minority cases, the infection will advance to clinical stage
or viral disease will be aggravated or clinical stage will be prolonged if the amount of endog-
enous neutralizing antibodies produced in the host is not high enough to neutralize all specific
viruses during the incubation or clinical stage of infection. This is how acute and chronic
infections are established.
Cellular immunity consists of two major functional mechanisms in controlling viral infec-
tion [46–48], one is to kill infected cells by cytotoxic T cells that not only contribute to patho-
logical changes of viral disease, but also release viruses for new rounds of infection if not
neutralized. The impacts of killing infected cells by the specific immunity are similar to cy-
topathic effects of viruses. The other is to inhibit replication of viruses in the infected cells
by cytokines, which will reduce the number of released viruses. From controlling infection
point of view, the cellular immunity can be counterproductive or helpful dependent on net
effect of two actions (the amount of virions released) as well as the level of specific neutral-
izing antibodies. A difference in tempo of clearing viral infection between cellular and hu-
moral immunity is that the cellular immunity clears viral infection only after cells are virus
infected while the neutralizing antibody clears viruses before the infection takes place, one
step ahead of the cellular immunity (Figure 3). Humoral immunity of neutralizing antibody
is direct, decisively effective and required for controlling viral infection. Once new rounds
of infection were completely blocked by sufficient amount of neutralizing antibodies, the
viral infection in the already infected cells will be cleared by virus secretion, cytopathic ef-
fects of viral replication, cell turnover or the cellular immunity. Alternatively, the viral infec-
tion will be restricted to those already infected cells if the infected cells were long-lived,
implying that viral infection has been brought under control with the neutralizing antibody.
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Figure 3. Differences in tempo and efficiency of clearing viral infection between neutralizing antibody and antivirals.
(A) Administrated neutralizing antibody immediately neutralizes extracellular viruses and protect uninfected cells; (B)
administrated small molecule inhibitor first allows virus to infect cells then starts inhibiting viral replication in infected
cells. It cannot immediately and completely remove viremia.
A chronic HBV infection is usually maintained by new rounds of infection. The chronic
infection can be spontaneously cleared if the level of endogenous neutralizing antibodies is
high and can neutralize all released viruses to stop new rounds of infection. For instance,
spontaneous clearance of chronic HBV infection occurs at annual rates of 1–2% and is featured
with seroconversion of HBsAg to anti-HBs antibody [49, 50].
2.1.4. A main risk that will prolong HBV infection course is extracellular viruses, and a main target in
treating viral diseases is extracellular viruses
Clearly, to cure HBV infection, it is essential and also efficient to interrupt infection course that
consists of repeated rounds of infection.
There are three consequent scenarios during the course of hepatitis B: one is the infected cells
become lost, resulting in releasing more virions as a consequence of cytopathic effects of
infected HBV, cell turnover or destruction by cellular immunity; the second one is the infection
is spontaneously cleared from infected cells by virus secretion or/and cellular immunity that
reduces production and release of viruses, a same outcome as inhibiting viral replication by
antivirals, and the third one is the infected cells are relatively long-lived (non-cytopathic
infection) and producing and releasing low or high level of viruses. A shared main conse-
quence produced by each scenario is releasing viruses. Thus, a main target in treating HBV
infection should be the extracellular viruses, which cause new rounds of infection. Direct
antivirals like NAs are not agents that can directly counter the extracellular viruses. Overall
effectiveness of treating chronic HBV infection will be significantly improved if neutralizing
antibodies are employed.
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2.2. HBV infection course and persistence
HBV infection is known for long incubation period that may last up to 6 months (average
2–3 months) [51, 52] before occurrence of clinical symptoms of acute HBV infection. We
believed that multiround infection occurs during the incubation period. Duck hepatitis B
virus (DHBV) experimental infection was utilized to verify this understanding of HBV in-
fection dynamics during the incubation period. Ducklings were inoculated with high
DHBV inoculation dose, and three animals were daily sacrificed for 7 days after inocula-
tion. Viral core protein was stained on liver sections, and DHBV DNA was detected in liver
tissues [45]. As shown in Figure 4A and B, DHBV infection rapidly expanded from a few
clusters of initially infected cells in the infected livers and reached a full-blown infection in
7 days, showing there were repeatedly new rounds of infection that expanded the infection
scope in the livers, even under the circumstances of experimental infection that used a very
large inoculum.
Figure 4. Multiround infection during the incubation period of DHBV infection. Viral replicative intermediates (A) and
antigen-staining cells (B) were detected in livers of DHBV-infected ducks. Three ducks were sacrificed at the indicated
days postinfection, and replicative intermediates were extracted from the liver. The viral DNA was detected by hybrid-
ization. The percent antigen-staining hepatocytes in some of the samples is indicated at the top of the lanes.
Are there continuously new rounds of infections after the full-blown HBV infection was
established?
Current theory views that chronic HBV infection is a consequence of the host’s insufficient
T-cell immunity that cannot kill all HBV-infected cells or cannot clear HBV infection from
infected cells [53, 54], implying chronic HBV infection is a simple extension of the initial or
early HBV infection; the hepatocytes, once infected with HBV, are long-lived and constant-
ly infected with the same initial viruses during chronic course.
However, such view is not supported by experimental and clinical evidence.
New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology
http://dx.doi.org/10.5772/66083
381
To investigate whether DHBV infection and DHBV-infected cell populations are stable after
liver was fully infected, 3-day-old ducklings were inoculated with a large inoculum containing
both DHBV 3 and 16 viruses at 1:1 ratio. The first biopsy was conducted at day 11 by which
the liver was fully infected, and then, series of liver biopsies were performed every 3 weeks.
Distinct genetic markers in two viral genomes allowed us to monitor kinetic changes in DHBV
3 and 16 singly and dually infected populations by determining cccDNA genotypes at single
nucleus level. It was found that majority of hepatocytes were singly infected and nearly 20%
of cells exhibited dual infection with both viruses at day 11 postinfection (p.i.) (Figure 5). We
detected new rounds of infections at each of 5 time points after day 11 because the fraction of
DHBV3-infected cells was expanding, but the expansion occurred in only singly infected
fashion, suggesting that already infected cells resisted superinfection while the new rounds of
infection were occurring. It also suggested occurrence of viral clearance in DHBV-infected liver,
which generated uninfected cells for new rounds of infection. This viral clearance conclusion
is consistent with data showing that the fraction of DHBV16-infected cells was decreased from
80% at day 32, to about 40% at day 131 p.i., and at least 40% of DHBV16-infected cells either
cleared the infection or were eliminated, which triggered regeneration of hepatocytes. Either
of two scenarios would produce uninfected cells targeted by new rounds of infection. The
results suggest DHBV infection even after the full infection was established in the liver remains
dynamic and is featured with new rounds of infections.
Figure 5. Repeated new rounds of infection after a liver was fully infected. Three-day-old ducklings (n = 20) were in-
fected with an inoculum containing both DHBV3 and 16. Six biopsies were performed on one animal at day 11, 32, 66,
88, 109 and 131 days postinfection (shown in this figure). cccDNA genotypes were determined by sequencing PCR
products amplified from cccDNA released from single individual nuclei. DHBV3-infected cells were expanding, while
DHBV16-infected cells were decreasing during the period of six times of biopsies, suggesting ongoing viral clearance
and new rounds of infection. As a quality control for our procedure, the same number of nuclei isolated from DHBV3
and DHBV16 singly infected livers was mixed and single individual nucleus was sorted into individual well of 96-well
plates for PCR amplification and sequencing. No dual infections were detected in 128 mixed nuclei, suggesting that
our procedure for detection is valid.
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The results on clearing of DHBV16 cccDNA and new establishing of DHBV3 cccDNA pool
from new rounds of infection are consistent with the early reports, in which a replication
defective pre-core mutant or revertants successfully spread infection and became the predom-
inant viral population following elimination of wild type (WT) or the initially inoculated
viruses (Figure 6) [55, 56]. Taken together, all results suggest that a chronic DHBV infection is
not a simple extension of the initial infection because the initial infection was cleared and the
early cccDNA genotypes were replaced. Rather chronic DHBV infection course is dynamic and
consists of viral clearance and new rounds of infection. Thus, repeatedly new rounds of
infection maintain the persistence of viral cccDNA and prolong the course of chronic infection.
Figure 6. WT DHBV was being replaced over time. The fraction of WT DHBV DNA in serum of four DHBV-infected
ducks was determined by PCR sequencing assay and plotted against the time postinfection. The kinetics of replacing
WT DHBV infection suggests DHBV infection in fully infected livers remains dynamic and featured with clearing WT
and new rounds of infection with MT.
These conclusions are supported by clinical HBV infection data.
It is well known that WT HBV infection is frequently replaced with mutant (MT) infection [25,
57–82] in untreated chronic HBV-infected patients. For instance, naturally occurring pre-core,
core, pre-S and S mutants became only or dominant viral population following the WT was
being eliminated from infected livers during natural course of chronic HBV infection. The data
strongly imply that WT or early HBV infection is frequently cleared at cccDNA level during
chronic HBV infection. It is notable that such cccDNA clearance naturally occurs without
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intervention. This understanding is consistent with cccDNA clearance in adult patients with
acute HBV infection in which HBV infection is naturally resolved, and no antiviral treatment
is needed.
Available data also suggest that HBV WT is replaced with HBV MT in NAs-treated chronic
HBV-infected patients as evidenced by emergence of drug resistant mutant infection [25, 82].
The drug mutant infection that may not bear drug resistant phenotypes was also frequently
detected in new generation of NAs-treated patients. A recent report shows that approximately
50% of patients treated with tenofovir (TDF) who remained viremic, developed pol/RT mutant
infection though none of patients showed the drug resistance phenotypes [83]. The frequency
of mutant infection in this report may be still underestimated because only the pol/RT sequence
was analyzed. The observation that drug-related mutants spread following elimination of WT
during NAs treatment suggests frequent viral clearance at cccDNA level and new rounds of
infection with mutants.
3. New strategy and therapeutics for treating HBV infection guided by the
viral infection biology
We propose a new strategy for treating HBV infection. This strategy directly aims to establish
HBsAg seroconversion as early as possible through administrating sufficient amount of
specific neutralizing antibodies, which will constantly and completely neutralize extracellular
viruses to block repeated rounds of infection. This new strategy represents a paradigm shift
in treating HBV infection, which has been treated primarily by inhibiting viral replication.
3.1. Directly dealing with the huge pool of HBsAg in chronic HBV infection
As the evidence points out, chronic HBV infection is not a simple extension of the initial
infection, but is established and maintained by new rounds of infection. A unique situation in
HBV infection is that it produces a huge pool of subviral particles (HBsAg) that are 1000–10,000
fold higher than virions [84]. The HBsAg primarily depletes the limited amount of endogenous
neutralizing antibodies and leaves virions unneutralized and infectious. Current treatment
strategy and approved antivirals are not designed to deal with new rounds of infection, almost
impossibly deliver HBsAg seroconversion, and this is why current treatment rarely cures
chronic HBV infection. The key to curing chronic HBV infection is to establish HBsAg
seroconversion and to interrupt the infection course as early as possible by providing and
maintaining high level of HBV neutralizing antibodies until the amount of endogenous HBV
neutralizing antibodies exceeds the amount of HBV particles or all infected cells cleared HBV.
Advantages of the new strategy:
1. It directly immediately targets extracellular viruses and blocks the spread of infection;
2. It facilitates permanent and complete viral clearance in the liver;
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3. It significantly reduces side effects of treating HBV infection. Unlike NAs and interferon
that function intracellularly, the neutralizing antibody is to replenish a normal component
of the immunity, which is relatively deficient in face of a huge pool of HBsAg, and it mainly
functions extracellularly;
4. Neutralizing efficacy does not depend on efficiency of viral replication in infected cells.
4. Conclusions
In this paper, we analyze the deficiencies of current HBV treatment strategy and antivirals and
the reason why they cannot cure chronic HBV infection. We also review the viral infection
biology to fresh our understanding of general phases and natural course of HBV infection. We
conclude that a full-blown HBV infection is established and maintained through multiround
infection. We propose a new strategy for treating HBV infection. The core of this new strategy
is that we must achieve HBsAg seroconversion naturally or interventionally to effectively clear
HBV infection. Under the proposed strategy, a main target of the treatment is extracellular
viruses, and an effective therapeutics is specific neutralizing antibodies.
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